Salvage Therapy with 225Ас-PSMA in Third-Line Radionuclide Therapy in Patient With Anemia and Thrombocytopenia

Metastatic castration-resistant prostate cancer (mCRPC) is the final stage of this disease. Modern approaches to the treatment of the mCRPC patients include a wide range of drugs (hormonal therapy, chemotherapy, PARP inhibitors, radionuclide therapy with the osteotropic drug radium chloride 223 Ra and target radioligands ( 177 Lu-PSMA and 225 Ac-PSMA). The clinical example presented in the article shows the consistent application of various methods (lines) of radionuclide therapy in the treatment of a mCRPC patient. The possibility of successful use of radioligand therapy 225 Ac-PSMA in patients with significantly reduced hematological parameters against the background of a significant increase in the level of PSA.